

Global Lung Cancer Vaccine Market & Pipeline Outlook 2022

<https://marketpublishers.com/r/GDD43510DC8EN.html>

Date: December 2016

Pages: 150

Price: US\$ 2,000.00 (Single User License)

ID: GDD43510DC8EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Lung Cancer Vaccine Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are 9 lung cancer vaccines in advance Phase-II clinical trials followed by 8 vaccines Phase-I/II trials.

Lung cancer is emerging as one of the most lethal malignancy having high morbidity and mortality rates across the world. High mortality rates, high unmet medical necessities and modest efficacy of presently available lung cancer therapeutics have encouraged the demand for better and efficient lung cancer vaccines. More funds are being diverted into research and development segment to come up with lung cancer vaccine having high safety and efficacy profiles. Pharmaceutical companies have recognized the marketing potential of these vaccines in generating significant revenues and providing efficient medical care to patients across the world. Lung cancer vaccine market is largely untapped and offers significant opportunities to pharmaceutical companies to occupy large market shares across the globe.

At present majority of the lung cancer vaccines are in experimental stage and are still stuck in clinical trials due to which large unmet medical demands are still to be fulfilled. Boehringer Ingelheim and CureVac are developing lung cancer vaccine called CV9202 for the treatment of lung cancer which is at higher phase of clinical trials. GlaxoSmithKline is developing MAGE-A3 lung cancer vaccine which is also under

investigation for other malignancies. Cell Genesys pharmaceutical company is developing GVAX for lung cancer and many clinical end points have been achieved during investigation.

Early market introduction of these drugs will be the major factor responsible for the increased marketing potential. Over time, they are expected to generate significant revenues owing to their safety and efficacy levels but till then this gap will be filled by other therapeutics. Further, those lung cancer vaccines which will make late entry have to face competition with previously marketed lung cancer vaccines giving them severe competition. This shows that pharmaceutical companies have to introduce their products in market as soon as possible to occupy major market shares across the globe. Thus, impact of early entrant will be more in global market and help them to generate significant revenues for some time before entry of worthy competitors.

Many pharmaceutical companies have already introduces cancer vaccines in global market and lung cancer segment is expected to get its first contender in coming years. Addition of lung cancer vaccines in this segment will further increase the size of global cancer vaccine market. Several other products belonging to different cancer indication will be entering in the global market leading to further increase in the market size. Advent of lung cancer vaccines is expected to improve this situation by increasing present survival rates and improve quality of life. Introduction of lung cancer vaccines are expected to gain major market shares among other cancer vaccines due to large patient population as compared to other disease indication.

Contents

1. WHAT ARE CANCER VACCINES?

2. MECHANISM OF CANCER VACCINES

- 2.1 Idiotypic Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. OVERVIEW OF LUNG CANCER PROLIFERATION

- 3.1 Lung Cancer Invasion
 - 3.1.1 Transformation of Normal Cell into Cancerous Cell
 - 3.1.2 Tumor Heterogeneity & Cancer Stem Cells
 - 3.1.3 Dissemination of Tumor Cell & Cell Motility
- 3.2 Lung Cancer Metastasis
 - 3.2.1 Angiogenesis & Lymphangiogenesis
 - 3.2.2 Intravasation, Circulation & Extravasation

4. LUNG CANCER VACCINE MECHANISM

- 4.1 Mechanism of Lung Cancer Vaccination
- 4.2 Rationale for Using Lung Cancer Vaccines
 - 4.2.1 Regulatory T- Lymphocytes (Tregs)
 - 4.2.2 Macrophages

5. CLINICAL TRIALS OF LUNG CANCER VACCINES

6. GLOBAL LUNG CANCER INCIDENCE RATE

- 6.1 U.S
- 6.2 Europe
- 6.3 Asia
- 6.4 Rest of the World

7. GLOBAL LUNG CANCER VACCINE MARKET OVERVIEW

- 7.1 Current Market Scenario
- 7.2 Global Lung Cancer Vaccine Pipeline Overview
- 7.3 Global Lung Cancer Vaccine Market Future Prospects

8. NEED FOR PERSONALIZED BREAST CANCER VACCINES

9. LUNG CANCER VACCINE CLINICAL PIPELINE BY COMPANY & PHASE

- 9.1 Preclinical
- 9.2 Phase-I
- 9.3 Phase-II

10. NON SMALL CELL LUNG CANCER VACCINE CLINICAL PIPELINE BY COMPANY & PHASE

- 10.1 Research
- 10.2 Preclinical
- 10.3 Phase-I
- 10.4 Phase-I/II
- 10.5 Phase-II
- 10.6 Phase-II/III
- 10.7 Phase-III

11. SMALL CELL LUNG CANCER VACCINE CLINICAL PIPELINE BY COMPANY & PHASE

- 11.1 Phase-II

12. MARKETED LUNG CANCER VACCINE CLINICAL & PATENT INSIGHT

- 12.1 Epidermal Growth Factor Cancer Vaccine
- 12.2 Mycidac-C™
- 12.3 Racotumomab (Vaxira)

13. NO DEVELOPMENT REPORTED & DISCONTINUED LUNG CANCER VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 13.1 No Development Reported

13.2 Discontinued

13.3 Suspended

14. COMPETITIVE LANDSCAPE

14.1 Argos Therapeutics

14.2 Boehringer Ingelheim

14.3 Cadila Pharmaceuticals

14.4 CureVac

14.5 Eli Lilly

14.6 Galaxo

14.7 ImClone Systems

14.8 Inovio Pharmaceuticals

14.9 Merck

14.10 NewLink Genetics

14.11 Northwest Biotherapeutics

14.12 Ono Pharmaceutical

14.13 Oncothyreon Incorporation

14.14 OSE Immunotherapeutics

List Of Figures

LIST OF FIGURES

Figure 1-1: Categorization & Function of Cancer Vaccines

Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 3-1: Major Steps Involved in Cancer Invasiveness

Figure 4-1: Mechanism of Lung Cancer Vaccination

Figure 6-1: US – Lung Cancer New Incidence & Deaths, 2016

Figure 6-2: US – Lung Cancer New Incidence by Gender, 2016

Figure 6-3: US – Lung Cancer Deaths by Gender, 2016

Figure 6-4: Japan – Lung Cancer New Incidence & Deaths, 2016

Figure 6-5: Japan – Lung Cancer New Incidence by Gender, 2016

Figure 6-6: Japan – Lung Cancer Deaths by Gender, 2016

Figure 6-7: China – Lung Cancer Patients, 2016 & 2022

Figure 6-8: India – Lung Cancer New Incidence, 2016 & 2022

Figure 6-9: Canada – Lung Cancer Deaths by Gender, 2016

Figure 7-1: Global Lung Cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022

Figure 7-2: Global Lung Cancer Vaccine Clinical Pipeline by Phase (Numbers), 2016 till 2022

Figure 7-3: Global Non-small cell lung cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022

Figure 7-4: Global Non-small cell lung cancer Vaccine Clinical Pipeline by Phase (Number), 2016 till 2022

Figure 7-5: Global Lung Cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022

Figure 7-6: Global Lung Cancer Vaccine Clinical Pipeline by Phase (Numbers), 2016 till 2022

Figure 8-1: Overview of Personalized Cancer Vaccines Development

Figure 8-2: Methodology for the Development of Personalized Cancer Vaccine

Figure 8-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine

Figure 14-1: Inovio Pharmaceuticals Clinical Pipeline

Figure 14-2: NewLink Genetics Corporation Clinical Pipeline

Figure 14-3: Northwest Biotherapeutics Clinical Pipeline

I would like to order

Product name: Global Lung Cancer Vaccine Market & Pipeline Outlook 2022

Product link: <https://marketpublishers.com/r/GDD43510DC8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDD43510DC8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970